Tadalafil for the treatment of benign prostatic hyperplasia: When the moment does not add up

European Urology

Volumn 63, Issue 3, 2013, Pages 517-518

  Kaplan, Steven A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V; TADALAFIL;

EDITORIAL; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA;

EID: 84872927372     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.004     Document Type: Editorial

References (6)

1. C.G. Roehrborn, K.T. McVary, A. Elion-Mboussa, and L. Viktrup Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
2. H. Porst, E.D. Kim, A.R. Casabe LVHJ study team Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial Eur Urol 60 2011 1105 1113
3. C.G. Stief, H. Porst, D. Neuser, M. Beneke, and E. Ulbrich A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
4. F. Giuliano, S. Ückert, M. Maggi, L. Birder, J. Kissel, and L. Viktrup The mechanism of action for phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia Eur Urol 63 2013 506 516
5. R.B. Egerdie, S. Auerbach, and C.G. Roehrborn Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study J Sex Med 9 2012 271 281
6. R. Shabsigh, J. Kaufman, M. Magee, D. Creanga, D. Russell, and M. Budhwani A multicenter, double-blind, placebo-controlled trial to assess the efficacy of sildenafil citrate in men with unrecognized erectile dysfunction Urology 76 2010 373 379